Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Dan T Vogl, Shebli Atrash, Sarah A Holstein, Omar Nadeem, Don M Benson, Jr, Maria Chaudhry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu, Sabrina Christine Collins, Xavier Parot, Jonathan L Kaufman

Blood blood.2024026124.

https://doi.org/10.1182/blood.2024026124

Published: 2024

Includes: Supplemental data

Journal Articles

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2024-198119

Published: 2024

Journal Articles

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Sikander Ailawadhi, Antje Hoering, J Christine Ye, Brea Lipe, Thomas R. Chauncey, Krisstina Gowin, David Calverley, Sarah A. Holstein, Erica L. Campagnaro, Adam Rosenthal, Jack Aiello, Saad Z. Usmani, Vincent Rajkumar, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3381.3.

https://doi.org/10.1182/blood-2024-209626

Published: 2024

Journal Articles

Increased Exceptional Response and Overall Survival Advantage for Patients with Multiple Myeloma Receiving Melphalan 200mg/m 2 Vs 140 Mg/m 2 Conditioning for Autologous Hematopoietic Stem Cell Transplantation

Sarah Tjards, Robin High, Matthew A Lunning, Tanya M. Wildes, Julie M. Vose, Muhamed Baljevic, Sarah A. Holstein, Christopher R D'Angelo

Blood (2023) 142 (Supplement 1): 4966.

https://doi.org/10.1182/blood-2023-179971

Published: 2023

Journal Articles

Modakafusp Alfa Demonstrates Type I Interferon-Mediated Innate and Adaptive Immune Enhancement in a Phase 1/2 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Gurpanna Saggu, Min Young Lee, Faith Dunbar, Reshma Singh, Kris Sachsenmeier, Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Jonathan L. Kaufman, Adarsh Joshi, Kaveri Suryanarayan, Sabrina Collins

Blood (2023) 142 (Supplement 1): 3316.

https://doi.org/10.1182/blood-2023-177909

Published: 2023

Journal Articles

Use of Geriatric Assessment and Genetic Profiling to Personalize Selection of Intensive Versus Low Intensity Chemotherapy in Older Adults with Acute Myeloid Leukemia (AML): Final Results of a Phase II Trial

Vijaya Raj Bhatt, Christopher Wichman, Thuy T Koll, Alfred Fisher, Tanya M. Wildes, Michael Haddadin, Ann Berger, James Olen Armitage, Sarah A. Holstein, Lori Maness, Krishna Gundabolu

Blood (2023) 142 (Supplement 1): 4265.

https://doi.org/10.1182/blood-2023-178112

Published: 2023

Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Blood (2022) 140 (Supplement 1): 10144–10147.

https://doi.org/10.1182/blood-2022-160451

Published: 2022

Journal Articles

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Ajay K. Nooka, Jonathan L. Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne A. Efebera, Brandi Reeves, Tanya M. Wildes, Sarah A. Holstein, Larry D. Anderson, Jr., Ashraf Z. Badros, Leyla O. Shune, Ajai Chari, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Paul G. Richardson, Saad Usmani, Peter M. Voorhees

Blood (2022) 140 (Supplement 1): 10154–10156.

https://doi.org/10.1182/blood-2022-162473

Published: 2022

Journal Articles

Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients’ Function and Health-Related Quality of Life Change with Treatment?

Vijaya Raj Bhatt, Christopher Wichman, Zaid S. Al-Kadhimi, Thuy T. Koll, Alfred L Fisher, Ann Berger, James O. Armitage, Sarah A. Holstein, Lori Maness, Krishna Gundabolu

Blood (2022) 140 (Supplement 1): 8991–8992.

https://doi.org/10.1182/blood-2022-156310

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Blood (2022) 140 (Supplement 1): 7278–7281.

https://doi.org/10.1182/blood-2022-162339

Published: 2022

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Blood (2022) 140 (Supplement 1): 1146–1149.

https://doi.org/10.1182/blood-2022-162313

Published: 2022

Journal Articles

Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don M. Benson, Jr., Kaveri Suryanarayan, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman

Blood (2022) 140 (Supplement 1): 1357–1359.

https://doi.org/10.1182/blood-2022-162253

Published: 2022

Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

Blood (2021) 138 (Supplement 1): 79.

https://doi.org/10.1182/blood-2021-149024

Published: 2021

Journal Articles

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

Dan T. Vogl, Jonathan L. Kaufman, Sarah A. Holstein, Shebli Atrash, Omar Nadeem, Murali Janakiram, Kaveri Suryanarayan, Yuyin Liu, Sabrina Collins, Xavier Parot, Maria Chaudhry

Blood (2021) 138 (Supplement 1): 898.

https://doi.org/10.1182/blood-2021-148463

Published: 2021

Journal Articles

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

Blood (2021) 138 (Supplement 1): 2852.

https://doi.org/10.1182/blood-2021-149028

Published: 2021

Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

Blood (2021) 138 (Supplement 1): 2723.

https://doi.org/10.1182/blood-2021-148533

Published: 2021

Journal Articles

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Blood (2020) 136 (8): 936–945.

https://doi.org/10.1182/blood.2020005288

Published: 2020

Includes: Supplemental data

Journal Articles

Effect of Using Multiagent Versus Single Agent Chemotherapy on Overall Survival (OS) of Older Adults with Acute Myeloid Leukemia (AML)

Vijaya R. Bhatt, MD, Valerie K Shostrom, Sarah A. Holstein, MD PhD, Zaid S. Al-Kadhimi, MD, Lori J. Maness, MD, Ann Berger, PhD APRN-CNS, AOCNS, FAAN, James O. Armitage, MD, Krishna Gundabolu, MBBS

Blood (2019) 134 (Supplement_1): 2155.

https://doi.org/10.1182/blood-2019-122679

Published: 2019

Journal Articles

The Effect of Age and CD34+ Stem Cell Dose on Autologous Hematopoietic Stem Cell Transplantation Outcomes in Multiple Myeloma - Single Institution Experience

Madeline Skousen, Sarah A. Holstein, MD PhD, Matthew A. Lunning, DO, FACP, Elizabeth R. Lyden, MS, Gilmore Sheree, BA, Kimberly Schmit-Pokorny, Nurse Manager, James O. Armitage, MD, Zaid S. Al-Kadhimi, MD, Julie M Vose, MDMBA, Muhamed Baljevic, MD

Blood (2019) 134 (Supplement_1): 2028.

https://doi.org/10.1182/blood-2019-131594

Published: 2019

Journal Articles

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Ken Flanagan, PhD, Muntasir M Majumder, MSc, BPharm, Romika Kumari, PhD, Juho Miettinen, PhD, Ana Slipicevic, PhD, Sarah A. Holstein, MD PhD, Michelle L. Varney, MS, Minna Suvela, MSC, Fredrik Lehmann, PhD, Nina N. Nupponen, PhD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3100.

https://doi.org/10.1182/blood-2019-125952

Published: 2019

NARROW

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase III Randomized Trial for Frail Newly Diagnosed Multiple Myeloma Patients Comparing Bortezomib- Lenalidomide-Dexamethasone (VRd-Lite followed by Len maintenance) with Daratumumab-Lenalidomide- Dexamethasone (DRd followed by Len+/- Dara Maintenance): SWOG S2209

Increased Exceptional Response and Overall Survival Advantage for Patients with Multiple Myeloma Receiving Melphalan 200mg/m 2 Vs 140 Mg/m 2 Conditioning for Autologous Hematopoietic Stem Cell Transplantation

Modakafusp Alfa Demonstrates Type I Interferon-Mediated Innate and Adaptive Immune Enhancement in a Phase 1/2 Study in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Use of Geriatric Assessment and Genetic Profiling to Personalize Selection of Intensive Versus Low Intensity Chemotherapy in Older Adults with Acute Myeloid Leukemia (AML): Final Results of a Phase II Trial

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients’ Function and Health-Related Quality of Life Change with Treatment?

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

Stem Cell Collection with Daratumumab (DARA)-Based Regimens in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) in the Griffin and Master Studies

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Effect of Using Multiagent Versus Single Agent Chemotherapy on Overall Survival (OS) of Older Adults with Acute Myeloid Leukemia (AML)

The Effect of Age and CD34+ Stem Cell Dose on Autologous Hematopoietic Stem Cell Transplantation Outcomes in Multiple Myeloma - Single Institution Experience

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only